Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)

被引：6

作者：

Yu, Tong ^{[1
]}

Jiang, Weibo ^{[1
]}

Wang, Yang ^{[1
]}

Zhou, Ying ^{[2
]}

Jiao, Jianhang ^{[1
]}

Wu, Minfei ^{[1
]}

机构：

[1] Jilin Univ, Norman Bethune Hosp 2, Dept Orthoped, 218 Ziqiang Rd, Changchun 130000, Jilin, Peoples R China

[2] Third Hosp Qinhuangdao, Dept Operating Room, Qinhuangdao 066000, Hebei, Peoples R China

来源：

INTERNATIONAL JOURNAL OF ONCOLOGY | 2024年 / 64卷 / 04期

关键词：

osteosarcoma; chimeric antigen receptor; T cell; chimeric antigen receptor T cell therapy; immunotherapy; IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT; MYELOID SUPPRESSOR-CELLS; MESENCHYMAL STEM-CELLS; GROWTH-FACTOR-BETA; SOLID TUMORS; GENETIC-MODIFICATION; BREAST-CANCER; ADOPTIVE IMMUNOTHERAPY; ANTITUMOR RESPONSES; CD44V6; EXPRESSION;

D O I：

10.3892/ijo.2024.5628

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Osteosarcoma (OS) is a frequently occurring primary bone tumor, mostly affecting children, adolescents and young adults. Before 1970, surgical resection was the main treatment method for OS, but the clinical results were not promising. Subsequently, the advent of chemotherapy has improved the prognosis of patients with OS. However, there is still a high incidence of metastasis or recurrence, and chemotherapy has several side effects, thus making the 5-year survival rate markedly low. Recently, chimeric antigen receptor T (CAR-T) cell therapy represents an alternative immunotherapy approach with significant potential for hematologic malignancies. Nevertheless, the application of CAR-T cells in the treatment of OS faces numerous challenges. The present review focused on the advances in the development of CAR-T cells to improve their clinical efficacy, and discussed ways to overcome the difficulties faced by CAR T-cell therapy for OS.

引用

页数：23

共 279 条

[31] The Role of the VEGF-C/VEGFRs Axis in Tumor Progression and Therapy [J].